Eye drug developer Belite Bio stock soars 160% following $36M IPO

The company’s principal stockholder, Taiwan’s Lin BioScience … The company plans to use proceeds from the IPO in part to fund Phase 3 clinical testing for its drug candidate LBS-008 for …
( read original story …)

---

Search your Hotel